Thought Leadership
ICON experts frequently present at industry events and author or contribute to industry publications. The following are some recent articles.
- 27 January 2012
Professional Development Endpoint
Published in Scrip Clinical Research - December 2011. Colin Stanley is the new President of DOCS, ICON's contract resourcing business. He talked to Joanne Payne about the importance of global knowledge and a fortuitous job offer that led to where he is today.
- 23 January 2012
Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model
Bob Bauer, ICON's Vice President of Pharmacometrics, recently co-authored the article "Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model" in the June 2011 edition of the Journal of Pharmacokinetics and Pharmacodynamics.
- 18 January 2012
Automated immunoassay equipment platforms for analytical support of pharmaceutical and biopharmaceutical development
Pulblised in Bioanalysis magazine, authored by John Allinson, VP Biomarker Lab Services ICON Development Solutions. This article reviews the wide range of analytical equipment platforms commonly available from diagnostic and research companies - highlighting how these can be leveraged within the context of a bioanalytical laboratory. Further, John explains how the use of immunoassay automation can improve and enhance both the quality of the science as well as assist in the management of the laboratory – including increasing analytical capacity and throughput.
- 17 January 2012
published in December 2011, co-authored by Melany Adamcio, IDS Medical Monitor Assoc, featuring a Phase I study of a fully human monoclonal antibody (MDX-1303 ) to characterize the safety, tolerability, immunogenicity, and PK/PD in healthy human subjects
Published in December 2011, co-authored by Melany Adamcio, IDS Medical Monitor Assoc, featuring a Phase I study of a fully human monoclonal antibody (MDX-1303 ) to characterize the safety, tolerability, immunogenicity, and PK/PD in healthy human subjects
- 10 January 2012
Concomitant blockade of 5-HT1A receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study
Co-Authored by Dr. John Connell of ICON Development Solutions
- 18 October 2011
Clamping Down
ICT - November, 2011. Glucose clamps offer more adaptable and reproducible procedures than ever before, and this article highlights the latest changes of this valuable tool for the development of new agents to treat Type 1 and Type 2 diabetes.
- 07 September 2011
Life Science Leader - A new Paradim for Strategic Partnerships
John Hubbard, Ph.D., senior VP and worldwide head of development operations for Pfizer, talks about Pfizer's strategic partnering with two CROs, ICON and PAREXEL, as preferred clinical trial outsourcing providers.
- 01 September 2011
Life Science Leader - Outsourcing Insights
Benefit From Clinical Trials In Emerging Markets While Limiting Risk Exposure
- 22 August 2011
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
The Lancet: Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
- 20 August 2011
The Lancet: The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
The Lancet: The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
